Delhi, India (PressExposure) May 04, 2007 -- Argentine scientists claimed to have cloned four such cows whose milk would contain human insulin. The scientists anticipate that if this attempt is successful itâll result in diminishing the costs of treatment for diabetes, as reported by Reuters on April 17, 2007.
The cloned animals, which are still calves, are expected to begin producing 'insulin infusedâ milk on reaching adulthood.
Bio Sidus, the company spearheading the project, intends to launch a pharmaceutical dairy where this new breed of cows can be accommodated in future. The objective is to produce adequate amount of human insulin at a cost thatâs lower than the currently available insulin.
"This model of a genetically modified cow allows us to produce large quantities of products at very low cost," said Marcelo Criscuolo, managing director, in a statement that Reuters published on April 17, 2007.
For producing pharmaceutical products such as insulin from the cowâs milk, human gene of interest is inserted in to an embryo prior to placing it into a surrogate mother cow. A gene for insulin was used in this case. After obtaining milk from the cloned cows, itâll be distilled and refined in order to extract insulin. Human proteins have been produced in cows and goats using similar techniques in the past as well.
Scientists are optimistic of the insulin produced in cowsâ milk to hit the market in a couple of years from now.
Thereâre approximately 200 million people suffering from diabetes across the globe. According to Argentine scientists only 25 insulin producing cows would suffice to meet the insulin demand of nearly 1.5 million diabetics in Argentina.
RNCOS report âNew Developments in Insulin Delivery System (2006)â notifies, âCurrent ambiance in insulin market comprises of strong marketing combined with clinical advocacy supporting newer products. There has been a lot of research and development done over the past 75 years for exploring alternative routes for universal administration of insulin, however none of the systems so far fully imitate insulin secretionâs physiology. The market for insulin delivery should be US$ 2 Billion year on year. Growth should continue at the same rate or more at least by 2020, when sales of insulin are estimated to surpass US$ 7.5 Billion.â
Key issues and facts analyzed in this report include: evaluation of current market trends, scope of the major insulin delivery systems all over the world, analysis of various challenges and opportunities before the industry, etc.
About RNCOS E-Services Pvt Ltd.:
RNCOS, incorporated in the year 2002, is an industry research firm. It has a team of industry experts who analyze data collected from credible sources. They provide industry insights and analysis that helps corporations to take timely and accurate business decision in today's globally competitive environment.
For more information visit: [http://www.rncos.com/Report/IM040.htm] Current Industry News: [http://www.rncos.com/blog]